Citius Oncology, Inc. (CTOR)
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Last price
- $0.51
- As of
Kresmion compiles this page from CTOR's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
CITIUS ONCOLOGY, INC. (CTOR): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-04.
See the full CTOR dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for CTOR on one page. Preview it with sample data, then open it live with a free account.
Preview the CTOR dossierActive events for CTOR
- high13F: large increase
CITADEL ADVISORS LLC added +413% to CTOR (2026Q2)
- mediumEarnings above estimates
Q3-2025: Beat consensus by 47.7% - EPS $-0.08 vs $-0.153 estimate
- lowEarnings below estimates
Q2-2026: EPS $-0.27 vs $-0.0102 estimate, -0.26 on a near-zero consensus
- lowEarnings below estimates
Q2-2026: EPS $-1.43 vs $-0.0102 estimate, -1.42 on a near-zero consensus
- mediumEarnings below estimates
Q2-2025: Missed consensus by 19.8% - EPS $-0.11 vs $-0.0918 estimate
FREE, NO ACCOUNT
Every event on CTOR, as it fires
You are seeing 5 of 8 events recorded on CTOR since 2026-05-16.
The five above landed across 5 days. The other 3 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
CTOR positions held by the managers we follow (2026Q2)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| CITADEL ADVISORS LLC FundCUSIP 17331Y109 · 2026Q2 | $59K | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CTOR
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
Going concern statement
CTOR's 10-Q filed Aug 14, 2026 states:
We will need to raise additional capital to support our operations beyond November 2026, which raises substantial doubt about our ability to continue as a going concern within one year after the date that the accompanying financial statements are issued.
Read the 10-Q on SEC EDGAR Every company with a going concern statement
More data on CTOR
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in CTOR on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on CTOR in the last 180 days.
Upstream: SEC EDGAR filings for CTOR
Kresmion, "CITIUS ONCOLOGY, INC. (CTOR) institutional holdings and SEC filings", data as of 2026-11-04, https://kresmion.com/research/CTOR. Upstream data: SEC EDGAR filings for CTOR.
Link to this data (HTML):
<a href="https://kresmion.com/research/CTOR">CITIUS ONCOLOGY, INC. (CTOR) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow CTOR on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to CTOR for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.